Our Founders Would Abhor What The USPTO Is Doing With The Patent System
From the make-patent-trolls-great-again? dept.
From the make-patent-trolls-great-again? dept.
Having a diversified and considered approach to marketing is the best way to spotlight your practice’s unique market offerings.
Drawing on more than a decade of data, the report equips law firms and corporate legal teams with actionable insights to better assess risk, refine strategy, and anticipate outcomes in today’s evolving workplace disputes.
We will reveal surprising, data-backed findings that challenges old ideas about IP staffing and technology.
The acquisition, Tradespace says, makes it the first AI-powered platform to support the complete IP lifecycle.
Sign up for this webinar as we reveal surprising patterns emerging from this new research -- insights that challenge long-held assumptions about staffing, technology, and the business role of IP.
Common law isn't supposed to be pay-per-view.
Takeaways from a Legalweek panel on evolving malpractice risks.
A patent owner’s statements about the scope of its patents must always be considered carefully.
The LF Dealmakers Forum reminds us of the need to stay vigilant, knowledgeable about the rules of the game, and flexible enough to adapt to policy decisions.
The current patent litigation funding market is a lot like a cup of coffee.
The confidential nature of the work done by IP attorneys adds complexity to marketing their achievements.
Depositions by Filevine help with scheduling, tracking goals, and trial prep.
From the *priorities* dept
The administration is throwing spaghetti at the wall to see what sticks.
The report’s presentation of data shows that modern patent litigation remains a vibrant and challenging pursuit for both plaintiffs and defendants.
The introduction of Cologuard after FDA-approval in 2014 has been a gamechanger in colon cancer diagnosis.
America’s authoritarian cosplay agency forgot basic IP law... again.